IS6251A - Not af mónóamín oxíðasa lötum fyrir framleiðslu ályfjum ætluðum til meðhöndlunar á offitu - Google Patents

Not af mónóamín oxíðasa lötum fyrir framleiðslu ályfjum ætluðum til meðhöndlunar á offitu

Info

Publication number: IS6251A
Authority: IS; Iceland
Prior art keywords: antidotes; obesity; manufacture; treatment; monoamine oxidase
Prior art date: 1999-08-16

Application number

IS6251A

Other languages

English (en)

Inventor

Roenzweig Pierre

Original Assignee

Sanofi-Synthelabo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-16

Filing date

2002-01-25

Publication date

2002-01-25

2002-01-25 Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo

2002-01-25 Publication of IS6251A publication Critical patent/IS6251A/is

Links

229940123685 Monoamine oxidase inhibitor Drugs 0.000 title 1
208000008589 Obesity Diseases 0.000 title 1
239000000729 antidote Substances 0.000 title 1
229940075522 antidotes Drugs 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
239000002899 monoamine oxidase inhibitor Substances 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Obesity (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Child & Adolescent Psychology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS6251A 1999-08-16 2002-01-25 Not af mónóamín oxíðasa lötum fyrir framleiðslu ályfjum ætluðum til meðhöndlunar á offitu IS6251A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP99116026A EP1078632A1 (en)	1999-08-16	1999-08-16	Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
PCT/EP2000/007917 WO2001012176A2 (en)	1999-08-16	2000-08-08	Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity

Publications (1)

Publication Number	Publication Date
IS6251A true IS6251A (is)	2002-01-25

Family

ID=8238777

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6251A IS6251A (is)	1999-08-16	2002-01-25	Not af mónóamín oxíðasa lötum fyrir framleiðslu ályfjum ætluðum til meðhöndlunar á offitu

Country Status (22)

Country	Link
EP (2)	EP1078632A1 (is)
JP (1)	JP2003506485A (is)
KR (1)	KR20020025971A (is)
CN (1)	CN1370067A (is)
AR (1)	AR025244A1 (is)
AU (1)	AU6441900A (is)
BR (1)	BR0013282A (is)
CA (1)	CA2377133A1 (is)
CZ (1)	CZ2002554A3 (is)
EA (1)	EA200200117A1 (is)
EE (1)	EE200200062A (is)
HK (1)	HK1046104A1 (is)
HU (1)	HUP0203601A2 (is)
IL (1)	IL147790A0 (is)
IS (1)	IS6251A (is)
MX (1)	MXPA02001649A (is)
NO (1)	NO20020770L (is)
PL (1)	PL364865A1 (is)
SK (1)	SK2162002A3 (is)
TR (1)	TR200200376T2 (is)
WO (1)	WO2001012176A2 (is)
ZA (1)	ZA200200738B (is)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1307182B1 (fr) *	2000-08-01	2005-03-30	Sanofi-Aventis	Composition pharmaceutique pour administration transdermique de befloxatone
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
SI1413331T1 (sl)	2001-01-26	2008-02-29	Schering Corp	Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
JP4711600B2 (ja)	2001-01-26	2011-06-29	シェーリングコーポレイション	シトステロール血症の処置のための置換アゼチジノン化合物の使用
DE10142660A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
AU2002331064B2 (en)	2001-08-10	2007-08-23	Palatin Technologies, Inc.	Peptidomimetics of biologically active metallopeptides
US7456184B2 (en)	2003-05-01	2008-11-25	Palatin Technologies Inc.	Melanocortin receptor-specific compounds
US7354923B2 (en)	2001-08-10	2008-04-08	Palatin Technologies, Inc.	Piperazine melanocortin-specific compounds
DE10142667B4 (de)	2001-08-31	2004-06-09	Aventis Pharma Deutschland Gmbh	C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel
DE10142722A1 (de)	2001-08-31	2003-03-27	Aventis Pharma Deutschland GmbH, 65929 Frankfurt	C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10142665B4 (de)	2001-08-31	2004-05-06	Aventis Pharma Deutschland Gmbh	C2-Disubstituierte Indan-1-one und ihre Derivate
DE10142662B4 (de)	2001-08-31	2004-07-08	Aventis Pharma Deutschland Gmbh	Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel
DE10142659A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142668A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142663B4 (de)	2001-08-31	2004-08-19	Aventis Pharma Deutschland Gmbh	C2-Disubstituierte Indan-1-ol-Systeme
DE10142666A1 (de)	2001-08-31	2003-03-20	Aventis Pharma Gmbh	Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142661B4 (de)	2001-08-31	2004-06-09	Aventis Pharma Deutschland Gmbh	Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
US7132415B2 (en)	2001-09-21	2006-11-07	Schering Corporation	Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
NZ537003A (en)	2002-07-18	2008-03-28	Cytos Biotechnology Ag	Hapten-carrier conjugates comprising virus like particles and uses thereof
CA2504878A1 (en)	2002-11-06	2004-05-27	Schering Corporation	Cholesterol absorption inhibitors for the treatment of demyelination
CN100439361C (zh)	2003-03-07	2008-12-03	先灵公司	取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
CN1756755A (zh)	2003-03-07	2006-04-05	先灵公司	取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja)	2003-03-07	2010-12-01	シェーリングコーポレイション	高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
DE10342672A1 (de) *	2003-09-16	2005-04-21	Bayer Chemicals Ag	Chirale Phosphane zur Verwendung in asymmetrischen Synthesen
CA2620476A1 (en) *	2005-06-02	2006-12-07	Jenrin Discovery	Mao-b inhibitors useful for treating obesity
US20070078172A1 (en) *	2005-06-16	2007-04-05	Jenrin Discovery	Mao-b inhibitors useful for treating obesity
JP5379692B2 (ja)	2006-11-09	2013-12-25	プロビオドルグエージー	潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2091948B1 (en)	2006-11-30	2012-04-18	Probiodrug AG	Novel inhibitors of glutaminyl cyclase
CA2679446C (en)	2007-03-01	2016-05-17	Probiodrug Ag	New use of glutaminyl cyclase inhibitors
US9656991B2 (en)	2007-04-18	2017-05-23	Probiodrug Ag	Inhibitors of glutaminyl cyclase
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009070533A1 (en) *	2007-11-29	2009-06-04	Complegen, Inc.	Methods of inhibiting steroyl coa desaturase
CA2726917C (en)	2008-06-04	2018-06-26	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en)	2008-07-16	2017-02-22	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
BR112012008346B1 (pt)	2009-09-11	2021-12-21	Vivoryon Therapeutics N.V.	Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
WO2011107530A2 (en)	2010-03-03	2011-09-09	Probiodrug Ag	Novel inhibitors
DK2545047T3 (da)	2010-03-10	2014-07-28	Probiodrug Ag	Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
EP2560953B1 (en)	2010-04-21	2016-01-06	Probiodrug AG	Inhibitors of glutaminyl cyclase
AR081626A1 (es) *	2010-04-23	2012-10-10	Cytokinetics Inc	Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2011133920A1 (en)	2010-04-23	2011-10-27	Cytokinetics, Inc.	Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
WO2012123563A1 (en)	2011-03-16	2012-09-20	Probiodrug Ag	Benz imidazole derivatives as inhibitors of glutaminyl cyclase
CN102267990B (zh) *	2011-06-03	2013-11-13	浙江工业大学	一种2,3-二氢苯并呋喃类衍生物及其制备与应用
JP2016514671A (ja)	2013-03-15	2016-05-23	シナジーファーマシューティカルズインコーポレイテッド	グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
CN105764916B (zh)	2013-06-05	2021-05-18	博士医疗爱尔兰有限公司	鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
PL3461819T3 (pl)	2017-09-29	2020-11-30	Probiodrug Ag	Inhibitory cyklazy glutaminylowej
CN110511208B (zh) *	2019-08-02	2020-08-25	浙江工业大学	N-2-吡啶基-2,3-二叠氮吲哚啉类化合物及其制备与应用
KR20230075912A (ko)	2021-11-23	2023-05-31	서제표	접이식 안경

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3153092A (en) *	1961-07-17	1964-10-13	Smith Kline French Lab	1-methyl-2-phenylcyclopropylamine derivatives
US3466236A (en) *	1965-11-09	1969-09-09	Eastman Kodak Co	Irradiation of aminocyclobutanones
AU5550780A (en) *	1979-04-26	1980-10-30	Merrell Toraude Et Compagnie	Alpha-halomethyl amines
FR2724171B1 (fr) *	1994-09-05	1997-01-03	Synthelabo	Derives de 3,3a,4,5-tetrahydro-1h-oxazolo(3,4-a)quinolein-1-one, leur preparation et leur application en therapeutique
HU224879B1 (en) *	1995-06-02	2006-03-28	Sanofi Aventis	Oxazolidinone derivatives, their preparation and pharmaceutical compositions containing these compounds
US5969146A (en) *	1995-10-11	1999-10-19	Synthelabo	Oxazolidin-2-one derivatives, preparation method therefor and therapeutical use thereof
US5955471A (en) *	1998-01-13	1999-09-21	Sk Corporation	Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same
AU3786299A (en) *	1998-05-04	1999-11-23	Neotherapeutics, Inc.	Novel serotonin-like 9-substituted hypoxanthine and methods of use
JP2002521433A (ja) *	1998-07-31	2002-07-16	ベラ・ファーマシューティカルズ・インコーポレイテッド	モクロベマイドを用いる、ある種の精神医学的および医学的異常の処置と予防の方法および組成物

1999
- 1999-08-16 EP EP99116026A patent/EP1078632A1/en not_active Withdrawn
2000
- 2000-08-08 PL PL00364865A patent/PL364865A1/xx not_active Application Discontinuation
- 2000-08-08 CA CA002377133A patent/CA2377133A1/en not_active Abandoned
- 2000-08-08 TR TR2002/00376T patent/TR200200376T2/xx unknown
- 2000-08-08 SK SK216-2002A patent/SK2162002A3/sk unknown
- 2000-08-08 EE EEP200200062A patent/EE200200062A/xx unknown
- 2000-08-08 HU HU0203601A patent/HUP0203601A2/hu unknown
- 2000-08-08 JP JP2001516522A patent/JP2003506485A/ja not_active Withdrawn
- 2000-08-08 CN CN00811699A patent/CN1370067A/zh active Pending
- 2000-08-08 IL IL14779000A patent/IL147790A0/xx unknown
- 2000-08-08 EP EP00951508A patent/EP1210080A2/en not_active Withdrawn
- 2000-08-08 KR KR1020027001959A patent/KR20020025971A/ko not_active Withdrawn
- 2000-08-08 HK HK02107811.0A patent/HK1046104A1/zh unknown
- 2000-08-08 CZ CZ2002554A patent/CZ2002554A3/cs unknown
- 2000-08-08 BR BR0013282-9A patent/BR0013282A/pt not_active Application Discontinuation
- 2000-08-08 WO PCT/EP2000/007917 patent/WO2001012176A2/en not_active Ceased
- 2000-08-08 AU AU64419/00A patent/AU6441900A/en not_active Abandoned
- 2000-08-08 EA EA200200117A patent/EA200200117A1/ru unknown
- 2000-08-08 MX MXPA02001649A patent/MXPA02001649A/es unknown
- 2000-08-15 AR ARP000104209A patent/AR025244A1/es unknown
2002
- 2002-01-25 IS IS6251A patent/IS6251A/is unknown
- 2002-01-28 ZA ZA200200738A patent/ZA200200738B/xx unknown
- 2002-02-15 NO NO20020770A patent/NO20020770L/no unknown

Also Published As

Publication number	Publication date
MXPA02001649A (es)	2002-10-23
EP1078632A1 (en)	2001-02-28
WO2001012176A3 (en)	2002-03-21
WO2001012176A2 (en)	2001-02-22
IL147790A0 (en)	2002-08-14
AU6441900A (en)	2001-03-13
HUP0203601A2 (hu)	2003-02-28
CZ2002554A3 (cs)	2002-05-15
CN1370067A (zh)	2002-09-18
CA2377133A1 (en)	2001-02-22
SK2162002A3 (en)	2002-07-02
AR025244A1 (es)	2002-11-13
NO20020770L (no)	2002-04-16
HK1046104A1 (zh)	2002-12-27
BR0013282A (pt)	2002-04-23
TR200200376T2 (tr)	2002-06-21
EA200200117A1 (ru)	2002-06-27
KR20020025971A (ko)	2002-04-04
JP2003506485A (ja)	2003-02-18
EE200200062A (et)	2003-04-15
NO20020770D0 (no)	2002-02-15
EP1210080A2 (en)	2002-06-05
PL364865A1 (en)	2004-12-27
ZA200200738B (en)	2003-03-26

Publication	Publication Date	Title
IS6251A (is)	2002-01-25	Not af mónóamín oxíðasa lötum fyrir framleiðslu ályfjum ætluðum til meðhöndlunar á offitu
DK1144395T3 (da)	2005-08-15	2-amino-benzoxazinon-derivater til behandling af fedme
IS6806A (is)	2003-05-05	Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum
DK1143977T3 (da)	2005-08-15	2-oxy-benzoxazinonderivater til behandling af obesitas
DK1459749T3 (da)	2006-01-09	(S,S)-reboxetin til behandling af inkontinens
NO20040933L (no)	2004-03-03	Nye gamma-sekretaseinhibitorer.
DK1352897T3 (da)	2007-04-10	Adamantanderivater til behandlingen af inflammatoriske sygdomme, immunsygdomme og cardiovaskulære sygdomme
DK1423381T3 (da)	2007-05-07	17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme
IS6286A (is)	2002-02-26	Efnasambönd til meðhöndlunar á blóðþurrð
DK1343773T3 (da)	2007-02-05	Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK0927555T3 (da)	2012-01-23	Anvendelse af cyclooxygenase-2-hæmmere til behandling og forebyggelse af tumorer, tumorrelaterede forstyrrelser og kakesi
IS2223B (is)	2007-03-15	Aðferð til framleiðslu á 5-sýanóþalíði
DK1803718T3 (da)	2008-10-27	4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
DK1506041T3 (da)	2008-01-28	Inbandronsyre til behandling og forebyggelse af osteoporose
DK1380121T3 (da)	2007-12-27	Fremgangsmåde til fremstilling af oxazolidinoner
NO20045554L (no)	2004-12-20	Fremgangsmate for behandling av diabetes
IS7275A (is)	2004-05-21	Samsetning fyrir hollegg og notkun á henni
DK1200114T3 (da)	2009-08-03	PPAR delta inhibitorer til behandling af kardiovaskulære sygdomme
DK1569634T3 (da)	2007-09-10	Anvendelse af en PPAR-agonist og metformin til behandling af fedme
DK1434588T3 (da)	2011-08-15	2-(amino-3,4-dioxo-1cyclobuten-1-yl)aminoalkylsyrederivater til behandling af smerte
DK2845594T3 (da)	2022-03-07	Anvendelse af dihydroimidazoloner til behandlingen af hunde.
DK1530462T3 (da)	2011-02-14	1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
DK1229906T3 (da)	2008-02-11	Mesoprogestiner til behandlingen og forebyggelsen af godartede, hormonafhængige, gynækologiske lidelser
DK1268482T3 (da)	2003-12-22	Pyranoindoler til behandling af glaukom
NO20052471D0 (no)	2005-05-23	Fremgangsmate for fremstilling av 3-metyltiopropanal.